Mpox: “You can’t even think about isolating all suspected cases”

by Laura Richards

New cases of ⁢the ⁤disease⁣ every week and now more than a thousand deaths: African health authorities have ⁤been fighting Mpox disease for months. ⁣Although vaccination campaigns have begun, there appears to be ⁤no end to the epidemic⁣ in sight. Jean Kaseya,director of the African health ​authority CDC ⁤Africa,repeats every week in ‍his‍ situation ⁢reports: “Spox in Africa is ‌not under control.”

For⁢ Kaseya and⁣ other ⁣health​ experts, the situation has a sort of déjà vu feel. As during the Covid pandemic, the weaknesses‌ of⁢ the continent’s health infrastructure​ are​ becoming evident: too ‌little ⁤laboratory and testing capacity,⁣ but above all too little domestic vaccine production. The continent’s health‌ authorities are​ relying on rich countries to provide⁤ vaccines from their stockpiles to protect against the virus.

According to facts from Center for Disease Control and ‍Prevention and the World ⁤Health Organization (WHO) Mpox‌ cases in 20 African countries – the first case ⁢occurred in ​Angola last week. ⁢Since the‌ beginning of ​the ​year, the number of​ patients⁤ has risen to almost 60,000 and this year there have been 1,164 deaths linked to Mpox.

Monkeypox, formerly known ⁤as monkeypox, occurs repeatedly in central Africa, transmitted primarily from​ rodents to humans. The⁣ fact that large epidemics never occurred for‌ decades ‍is due, among other things, to the previously widespread smallpox ⁢vaccination. It also⁤ protects against closely related Mpox viruses. Smallpox⁢ has been considered eradicated since ⁤1980, so vaccinations ‍have been suspended.

In ‍mid-august, the Africa CDC and WHO declared the⁣ highest alert level due to the Mpox epidemic⁢ in Africa and the new, possibly more risky Ib variant. The aim is to encourage ⁢authorities around the world to be‌ more vigilant.

However, more than 90% of cases continue ‌to be recorded ⁢in Central Africa. ⁤95.5% of last week’s 2,680⁣ new⁤ cases also ⁢occurred in Congo, Uganda and Burundi.

Delays in‍ vaccination campaigns

By the first half of November, the DRC, Rwanda and Nigeria received a total of 280,000 vaccine doses. But vaccinations began⁣ with delays in Congo and Nigeria. Poor infrastructure in ​large ‍areas,lack of cooling options and electricity bottlenecks⁤ make vaccine distribution even more difficult,especially in rural regions.

Furthermore, ‍the vaccine doses ‍delivered so far ‍are ultimately just​ a drop in the ocean: when the alert​ was announced,​ Kaseya had already ⁤spoken of at least‍ ten million vaccine‌ doses that would be needed ‌on the continent to stop the‍ epidemic.

However, since not all countries record⁣ cases of childhood ⁢disease separately, data does not​ exist for ⁣all affected countries.

But⁤ existing ⁤Mpox vaccines have not yet been approved ⁤for children.‌ Now there is hope here,said Ngashi Ngongo,the Africa CDC’s ​Mpox lead,in the latest assessment on Thursday. Japan​ has promised the Democratic Republic of Congo​ three million doses of a vaccine also suitable for children aged one ⁣year and older. However, the approval process in the african⁢ contry is still⁣ pending.

distancing and hygiene measures,already attempted to minimize infections during the corona ​pandemic,can only have a limited affect,especially‌ in ⁢heavily affected⁢ eastern Congo. A total ⁢of⁣ around seven million people live here in⁤ extremely cramped conditions in refugee camps after fleeing armed fighting in the⁢ conflict-ravaged region.

“You ​can’t even think​ about isolating all suspected‍ cases because the population is enormous and there ‍are neither spaces nor structures to host⁢ them,” said‍ Agnese Commelli, a ⁣doctor with⁣ the humanitarian organization Doctors Without Borders in Goma, eastern Congo. .⁢ German Press‍ Agency.

Sick people wait and‍ see

Health authorities already have‍ difficulty registering cases.​ Only a small portion of suspected cases could be officially ‍confirmed. There are no rapid tests, samples must⁤ be sent to laboratories and patients,​ and the medical staff treating them⁢ only have days or weeks to know whether⁢ the infectious disease has ⁢been confirmed.

Many people turn to ⁢health​ services only when the disease⁢ is in an advanced stage, explains commelli. “They don’t walk four ‍kilometers or more ⁣to the nearest‍ health center ⁢just because they​ have a fever.They come when they feel worse and the rash has ​already progressed.” The ‍doctor also found that the ⁢fear of Mpox infection was⁢ not​ particularly pronounced: “It’s not Ebola.”

Relatives and neighbors often become infected when they go to the ⁣doctor, especially if people live close together. In ‌addition to the‌ characteristic ​rash,⁢ typical symptoms include‍ chills, fever and headache, muscle aches and back pain. ⁣Fatal cases occur mainly ​in regions​ with limited access to ⁢medical care. They often affect ⁣children, especially those suffering from ‌malnutrition, ⁤and people with weakened immune systems.

After ⁤suffering from Mpox disease, you develop an immunity⁣ against reinfection that lasts for years. People ⁣who are already ill thus⁤ initially do⁤ not need vaccination.“The more an epidemic spreads, the less useful vaccines will be,” says Commelli.

The arduous fight against the spread​ of the virus is already having consequences ⁣on other‌ areas of the continent’s healthcare system, as Commelli explains: The‌ prevention and ⁤treatment of ⁢other diseases such ​as malaria and cholera is affected by ⁢the fact that a ⁢large part of the⁣ population has already low are occupied⁤ by the Mpox -‍ the fight⁤ is​ limited.

Eva⁤ krafczyk, dpa

What are⁢ the main challenges in⁢ controlling the Mpox epidemic in africa?

Interview: ‌Unpacking the Mpox Epidemic‌ in Africa

Interviewer: Alice Roberts, Editor at Time.news

Expert: ⁢Dr.⁢ Jean Kaseya, Director of ​Africa CDC


Alice: Good afternoon, Dr. ‍Kaseya. Thank you for ⁤joining us ​today to ‍discuss the⁣ ongoing Mpox epidemic in ‍Africa. With over⁢ 60,000 cases and‍ more ‍than a thousand reported deaths this year, the situation seems​ dire.⁣ Can you provide us with a current overview of the crisis?

Dr.Kaseya: Good afternoon,Alice. Thank you for ‌having me. The situation with Mpox, formerly known as ⁣monkeypox, is indeed‍ concerning.We have seen a meaningful rise in cases across 20 African countries,⁢ notably ‍in Central Africa. ‍the epidemic is⁣ exacerbated by the weaknesses in our health infrastructure, much like⁤ what we encountered during the Covid pandemic.Our report each week consistently highlights that “Mpox in Africa is ⁣not under⁤ control.”

Alice: You mentioned the weaknesses in the health infrastructure. What specific⁤ challenges are you facing in terms of testing‌ and vaccination?

Dr. Kaseya: There are a⁣ number of⁤ challenges. First and foremost is the limited laboratory and testing capacity across ​the ​continent. This hampers our ​ability to quickly diagnose and respond‌ to outbreaks. Additionally, ‍the production of ⁢vaccines‌ is heavily‍ reliant⁣ on imports from wealthier nations, leading to delays and uneven distribution. for example, even though we have received some vaccine doses, the rollout ⁣has ‌faced significant delays due to poor infrastructure, especially in‌ regions that struggle with reliable electricity and cooling options needed for vaccine storage.

Alice: It ⁤seems that we are witnessing a sort of déjà vu. How⁣ do you think the lessons learned from the Covid ⁣pandemic can be applied to this current crisis?

Dr. Kaseya: Absolutely, the parallels are striking. One key lesson is the ‍importance​ of investing ⁤in local health infrastructure. We​ must prioritize building our laboratory capabilities and improve vaccine production domestically. We need ‍to establish a robust public health system that can respond swiftly to outbreaks. The joint efforts⁤ of the Africa CDC and WHO have⁣ been vital⁣ in raising awareness ‍and alert levels, but increased local production and support are imperative for long-term solutions.

Alice: You highlighted the low vaccination⁤ rates and the difficulty in administering them. What steps ‍are being taken currently to enhance vaccination campaigns?

Dr. ‌Kaseya: We are actively coordinating with member states, ensuring that thay receive adequate doses and technical support for vaccination campaigns. By the first half‍ of November, countries like ​the DRC, Rwanda, ⁢and nigeria received a total of 280,000 vaccine doses. However,we⁤ are​ working closely ⁣with local ⁤health authorities‌ to address the logistical challenges and to streamline the vaccination process,making use of mobile clinics,for instance,to ⁣reach remote communities.

Alice: ​ Given that over ⁢90% of ‍cases are recorded in Central Africa, particularly in regions like Congo, Uganda, ⁣and ​Burundi, ⁤what strategies ⁢do you have in‌ place to‌ specifically target these ⁢areas?

Dr. Kaseya: ‍ Our strategy involves surveillance, targeted interventions, and community engagement. We need to educate the populations most at⁣ risk about transmission and prevention measures while enhancing our tracking efforts. Collaborating with ‌local NGOs⁤ and ⁤health workers allows us to adapt our strategies‌ to the unique‌ challenges faced in these regions. Additionally, ‌we are urging international communities to assist‌ beyond just vaccine⁤ donations but also help in building enduring infrastructure.

Alice: ​ Thank you for sharing ⁤these insights,⁣ Dr.Kaseya. As the director of the Africa CDC, ⁢what message would⁢ you like to convey to the global community regarding the ‍Mpox situation in Africa?

Dr. Kaseya: I would like to emphasize the urgency ⁢of the ⁣situation and the need for collaborative⁣ support.While we are grateful⁣ for the ‍assistance received, we need sustained commitment and investment in African health systems.The fight against Mpox is not just ​Africa’s problem—it’s a global health issue.We must work together to ensure that no region‍ is left ⁤vulnerable to preventable diseases.

Alice: Thank you, Dr. Kaseya. Your insights have​ been incredibly valuable. We wish you and your team the best in⁣ your continued efforts to combat Mpox in Africa.

Dr. Kaseya: Thank you,Alice. It’s vital that we keep this conversation going as we work towards a healthier future.

End of Interview

You may also like

Leave a Comment